Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)

12 de noviembre de 2026 actualizado por: Merck Sharp & Dohme LLC

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Participants With Rheumatoid Arthritis

Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. Researchers are doing this trial to learn if a trial medicine called MK-8690 can treat symptoms of active RA in people who are taking MTX.

The goal of this study is to learn if MK-8690 works better than placebo to improve RA symptoms.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • Fase 2

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has a clinical diagnosis of rheumatoid arthritis (RA) and fulfillment of 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria
  • Has active disease defined as ≥6 tender joints (based on 68 joints) and ≥6 swollen joints (based on 66 joints)
  • Has current treatment with oral or parenteral methotrexate (MTX) therapy
  • Has history of one of the following: a) biologic disease-modifying antirheumatic drug (bDMARD) naïve, or b) bDMARD-inadequate response (IR)/intolerant up to a maximum of 1 class of bDMARD

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than RA (such as, but not limited to, psoriatic arthritis, systemic lupus erythematosus, gout, systemic sclerosis, myositis, pseudogout, etc.), or any other condition that may interfere with the assessment of RA
  • Has a transplanted organ and requires continued systemic immunosuppression
  • Has a history of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for <5 years before randomization
  • Is known to be infected with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus
  • Has an active infection

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Period 1: MK-8690

Participant will receive MK-8690 subcutaneous (SC) for 12 weeks

Solution for SC injection

Otros nombres:
  • PRA052

Background therapy - variable dose strength with route of administration per approved product label

Comparador de placebos: Period 1: Placebo

Participant will receive placebo SC for 12 weeks

Background therapy - variable dose strength with route of administration per approved product label

Solution for SC injection

Experimental: Extension Period

After completing Period 1 participants will receive MK-8690 SC for 40 weeks.

Solution for SC injection

Otros nombres:
  • PRA052

Background therapy - variable dose strength with route of administration per approved product label

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12
Periodo de tiempo: Week 12

ACR response is a well-established composite measure used in clinical trials to evaluate clinical response in rheumatoid arthritis (RA). ACR50 response is defined as 50% or greater improvement in tender joint count (TJC) based on 68 joints, swollen joint count (SJC) based on 66 joints, and ≥3 of the 5 remaining components of Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment of Disease Activity (PGA), Patient Global Assessment of Disease Activity (PtGA), Patient Assessment of Pain Severity, and high-sensitivity C-reactive protein (hsCRP). ACR50 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 50% improvement in the composite measure. The percentage of participants achieving ACR50 at Week 12 will be presented.

Week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants Who Experience One or More Adverse Events (AEs)
Periodo de tiempo: Up to approximately 70 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience 1 or more AEs will be presented.

Up to approximately 70 weeks
Number of Participants Who Discontinue Study Intervention Due to an AE
Periodo de tiempo: Up to approximately 48 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be presented.

Up to approximately 48 weeks
Percentage of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12
Periodo de tiempo: Week 12

ACR20 response is defined as 20% or greater improvement in TJC based on 68 joints, SJC based on 66 joints, and ≥3 of the 5 remaining components of HAQ-DI, PGA, PtGA, Patient Assessment of Pain Severity, and hsCRP. ACR20 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 20% improvement in the composite measure. The percentage of participants achieving ACR20 at Week 12 will be presented.

Week 12
Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 12
Periodo de tiempo: Week 12

ACR70 response is defined as 70% or greater improvement in TJC based on 68 joints, SJC based on 66 joints, and ≥3 of the 5 remaining components of HAQ-DI, PGA, PtGA, Patient Assessment of Pain Severity, and hsCRP. ACR70 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 70% improvement in the composite measure. The percentage of participants achieving ACR70 at Week 70 will be presented.

Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) based on Disease Activity Score 28 Using C-Reactive Protein (DAS28-CRP) at Week 12
Periodo de tiempo: Week 12

The DAS28-CRP is a continuous composite measure of RA activity that includes the following components:

  • TJC (out of a total of 28 joints)
  • SJC (out of a total of 28 joints)
  • hsCRP
  • PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. LDA is indicated by a DAS28-CRP score of ≤3.2. The percentage of participants achieving LDA at Week 12 will be presented.
Week 12
Change from Baseline in DAS28-CRP
Periodo de tiempo: Baseline and at designated timepoints up to Week 52

The DAS28-CRP is a continuous composite measure of RA activity that includes the following components:

  • TJC (out of a total of 28 joints)
  • SJC (out of a total of 28 joints)
  • hsCRP
  • PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. The change from Baseline at designated timepoints up to Week 52 in the DAS28-CRP will be presented.
Baseline and at designated timepoints up to Week 52
Percentage of Participants Achieving LDA based on DAS28-CRP
Periodo de tiempo: At designated timepoints up to Week 52

The DAS28-CRP is a continuous composite measure of RA disease activity that includes the following components:

  • TJC (out of a total of 28 joints)
  • SJC (out of a total of 28 joints)
  • hsCRP
  • PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. Remission is indicated by a DAS28-CRP score of <2.6 and LDA by a DAS28-CRP score of ≤3.2. The percentage of participants achieving LDA at designated timepoints up to Week 52 based on DAS28-CRP will be presented.
At designated timepoints up to Week 52
Percentage of Participants Achieving Clinical Remission Based on DAS28-CRP
Periodo de tiempo: At designated timepoints assessed up to Week 52

The DAS28-CRP is a continuous composite measure of RA disease activity that includes the following components:

  • TJC (out of a total of 28 joints)
  • SJC (out of a total of 28 joints)
  • hsCRP
  • PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. Remission is indicated by a DAS28-CRP score of <2.6 and LDA by a DAS28-CRP score of ≤3.2. The percentage of participants achieving clinical remission at designated timepoints assessed up to Week 52 based on DAS28-CRP will be presented.
At designated timepoints assessed up to Week 52
Change From Baseline in the HAQ-DI Score
Periodo de tiempo: Baseline and Week 12

HAQ-DI is measure of physical function in RA clinical trials and is a 20-item questionnaire completed by the participant. The measure includes 8 domains assessing "dressing and grooming," "arising," "eating," "walking," "hygiene," "reach," "grip," and "activities." Participants respond on a 4-point scale ranging from 0 = "without ANY difficulty" to 3 = "UNABLE to do." The measure also captures the use of aids or devices and need for help from another person. The overall disability score is a summation of the highest score from each domain divided by the number of domains completed and ranges from 0 to 3 (worst disability). Clinically meaningful improvement in HAQ-DI for RA has been determined to be ≥0.22 points. The change from Baseline to Week 12 in the HAQ-DI will be presented.

Baseline and Week 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Medical Director, Merck Sharp & Dohme LLC

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

23 de noviembre de 2026

Finalización primaria (Estimado)

19 de octubre de 2027

Finalización del estudio (Estimado)

28 de noviembre de 2028

Fechas de registro del estudio

Enviado por primera vez

19 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

19 de octubre de 2026

Publicado por primera vez (Actual)

26 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 8690-004
  • MK-8690-004 (Otro identificador: MSD)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .